🇺🇸 FDA
Pipeline program

REC-3964

REC-3964-201

Phase 2 small_molecule terminated

Quick answer

REC-3964 for Recurrent Clostridioides Difficile Infection is a Phase 2 program (small_molecule) at RECURSION PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
RECURSION PHARMACEUTICALS, INC.
Indication
Recurrent Clostridioides Difficile Infection
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials